

# Index

- 2-heptyl-3-hydroxy-4-quinolone, 53, 74  
3-O-deacylase activity, 112  
 $\alpha$ -hemolysin, 52  
 $\alpha(2 \rightarrow 8)$  N-acetyl neuraminic acid (polysialic acid), 120  
 $\beta$ -lactamase (Bla), 58, 60, 66, 134  
 $\beta$ -lactam ring, 66  
 $\sigma^E$ , 40  
 $\sigma^E$  cell envelope stress response, 82  
 $\sigma^E$  response, 41  
 $\sigma^E$  stress-response pathway, 40
- A**  
A subunit, 75  
ABC transporters, 29  
Abiotic surface, 67  
Acellular pertussis vaccine, 111  
Acellular vaccines, 118  
*Acinetobacter baumannii*, 110  
*Acinetobacter baumannii* strain ATCC 19606, 111  
*Actinobacillus*, 36  
*Actinomycetemcomitans*, 36  
Activation of nuclear factor kappa B(NF-kB), 104  
Activation of proinflammatory response, 95  
Acute secretory diarrhea, 109  
Acyl chains, 53  
Acyl homoserine lactones (HSL), 53, 73  
Acyl link, 126  
Acylxyacyl-linked fatty acids, 126  
Adaptive immune system, 96  
Adaptive memory immune response, 118  
Adenylate cyclase hemolysis, 112  
Adherence properties, 67  
Adherent-invasive E. coli (AIEC), 53  
Adhesins, 19, 52, 96  
Adjuvant, 112, 118  
ADP-ribosyl transferase, 52  
Aerobic, 49  
Alginate-producing *P. aeruginosa*, 66  
Alkyl chain, 86  
(HlyAlpha hemolysinA), 52  
Alpha-configured glucosamine, 126  
Alternative complement pathway, 99  
Aluminium hydroxide, 108, 112  
Aluminum phosphate adjuvant, 111  
Alveolar epithelial cell membrane, 75  
Aminopeptidase, 54  
Anaerobic growth conditions, 49  
Animal models, 95  
Animal-based immunogenicity testing, 132  
Antibiotic, 12, 39, 56  
Antibiotic resistance, 66  
Antibiotics-loaded OMVs, 57  
Antibodies, 75  
Antibody complexes, 96  
Antibody response, 113  
Antibody-mediated protection, 108  
Antibody titer, 110  
Antidigoxin, 60, 134  
Antigen presentation, 96  
Antigen-presenting cells (APCs), 102, 114  
Antigen-receptor complex, 97  
Antigens, 11  
Antigen-specific IgG and IgM, 111  
Antigen-specific immune response, 133  
Anti-GFP antibody, 58  
Anti-Lewis-antigen, 53

**A (cont.)**

Anti-OMV IgG antibody, 123  
 Apical cytoplasm, 91  
 Apx toxin, 48  
 Associated laminin, 100  
 ATP binding cassette transporter, 92  
 Attacking phages, 36  
 Auto-aggregation, 66  
 Autoinducers, 53  
 Autolysins, 48  
 Autophosphorylation, 97  
 Autotransporter, 57  
 Autotransporter pathway, 92

**B**

“B-band” form, 38  
 B lymphocytes, 100  
 B subunits, 75  
 Baby rabbit complement, 120  
*Bacillus stearothermophilus*, 73  
 Bacterial envelope, 16  
 Bacterial lysis, 20, 30  
 Bactericidal Abs, 108, 124–126  
 Bactericidal antibody in serum, 108  
 Bactericidal titers, 126  
 Bactericidal/permeability increasing protein (BPI), 76  
 Bacteriolytic, 73  
 Bacteroides, 36  
 BALB/c mice, 112  
 Basement membrane-basophils, 96  
 B-cell activation, 96, 97  
 B-cell proliferative response, 98  
 B-cell superantigen, 98  
 Beta-configured glucosamine, 126  
 Biochemical pathways, 99  
 Biofilm, 37, 65  
 Biofilm formation, 66  
 Biogenesis of OMVs, 30, 82  
 Bioinformatic analysis, 132  
 Biopsied sections, 38  
 Biosynthesis of the pilus, 56  
 Bivalent capsular polysaccharide vaccines, 119  
 Bleb like structures, 10  
 Bleb off, 108  
*Bordetella bronchiseptica*, 112  
*Bordetella pertussis*, 111  
*Bordetella pertussis* Tohama strains, 112  
*Borrelia burgdorferi*, 36, 39  
 Brain microvascular endothelial cells, 76  
*Brucella melitensis*, 36

Bulging and pinching off, 11  
 Bulging of the OM, 82  
*Burkholderia pseudomallei*, 112

**C**

C3b protein, 100  
 C4b-binding protein, 100  
 C5 convertase, 100  
 C57BL/6 mice, 111  
 Cag pathogenicity island, 54  
 CagA, 54  
 cAMP, 49  
*Capnocytophaga ochracea*, 66  
 Capsid protein, 116  
 Capsular polysaccharide (CPS), 105  
 Carboxy-terminal truncated, 50  
 Cascade, 99  
 Cell envelope, 41  
 Cell envelope-localized proteins, 84  
 Cell lysis, 12  
 Cell proliferation, 102  
 Cell viability, 102  
 Cell wall, 3  
 Cell wall excretion, 5  
 Cell-mediated immunity, 101  
 Cellular-mediated immune (CMI), 113  
 Cerebrospinal fluid, 39  
 Channel-forming proteins, 16  
 Charge–charge interaction, 82  
 Charge–charge repulsion, 38  
 Chemotaxis, 100  
 Chimeric protein, 58  
 Chitinase activity, 52  
*Chlamydia psittaci*, 39  
*Chlamydia trachomatis*, 39  
 Chloramphenicol, 81  
 CHO cell assay, 49  
 Cholera toxin CT, 92  
 Cholera toxin, 1, 109  
 Chromosomal, 55  
 Chronic infection, 112  
 Chronic obstructive pulmonary disease (COPD), 97  
 CiF proteins, 52  
 Ciprofloxacin, 40  
 Classical complement pathway, 99  
 Cleavage, 100  
 Cluster of differentiation 86 (CD86), 102  
 Cluster randomized, 122  
 ClyA, 58  
 ClyA–GFP, 134  
 ClyA–GFP fusion protein, 135

- Co-aggregation, 66
- Co-aggregation of bacteria, 65
- Coiled-coil, 100
- Colloid bodies, 91
- Colonize, 38
- Colonizing bacteria, 38
- Common terminal pathway, 100
- Competent, 56
- Complement cascade, 53, 100
- Complement cascade activation, 96
- Complement system, 99
- Complement-mediated killing, 100
- Component C3, 100
- Confocal microscopy, 76
- Conformation of OMVs, 125
- Conformational change, 75
- Conjugation of mobilizable plasmids, 56
- Controlled Release System, 133, 134
- Conventional vaccine design, 132
- Core polysaccharide, 15
- CpG dinucleotide motif, 98
- (CpG) DNA, 96
- Cpx, 40
- Critical threshold density, 53
- Cross-links, 82
- Cross-links the BCR, 97
- Cross-protective vesicle vaccines, 132
- CT receptor, 49
- CT, 49
- C-terminal domain, 57
- C-terminus of ClyA, 60, 134
- Culture filtrates, 7, 148
- Cultured epithelial cells, 54
- Curvature protein, 81
- Curvature-inducing proteins, 86, 87
- Cysteines, 51
- Cytochrome C-independent apoptosis, 51
- Cytokines, 96
- Cytolethal distending toxin (CDT), 52
- Cytolysin A (ClyA), 49, 51
- Cytoplasm, 18
- Cytoplasmic membrane, 8
- Cytoplasmic proteins, 29
- Cytotoxic activity, 58
- Cytotoxic effect, 58
- Cytotoxin, 58
  
- D**
- Decarboxylates diaminopimelic acid, 8
- Decay, 8
- Defense function, 100
- Defense strategy of bacteria, 38
- degP*, 40
- degS*, 40
- DegS, 40
- Dehydration, 109
- Delivery vehicles, 110
- Dendritic cells, 76, 96
- Density gradient centrifugation, 20, 28
- Dermis, 39
- Detergent sensitivity, 82
- Detergent-treated OMVs, 29, 120
- D-glucosamine disaccharide, 126
- Diaminopimelate containing
  - GlcNac-MurNac tripeptide motif, 103
- Diaminopimelic acid, 8
- Diarrheal disease, 109
- Differential centrifugation, 20, 115
- Direct interaction with immune cells, 95
- Disruption of genes, 41
- Distinctive features, 93
- DNA, 19, 66
- DNA microarray, 132
- DNA packaging, 55
- DNA-containing OMVs, 66
- DNase, 66
- Double-blind, 122
- Downstream effector, 40
- Dukoral, 109
  
- E**
- Ecgp, 76
- EchoBASE database, 84
- Efficacy trial, 122
- EF-Tu, DnaK, GroEL, 29
- Electron microscopic techniques, 83
- Electron microscopy, 6, 38
- Electron-transparent zone, 8
- Endemic, 119
- Endocytosis, 75
- Endoplasmic reticulum, 75
- Endothelial cells, 96
- Endotoxic activity, 10, 112
- Endotoxins, 39
- Energy sink, 93
- Energy transfer, 93
- Engineered recombinant OMVs, 58
- Enterotoxigenic *E. coli* (ETEC), 36, 49
- Entrapped toxins, 48
- Envelope instability, 83
- Envelope stress-response pathway, 41
- Environmental factors, 38
- Enzymatic digestion, 28
- Enzyme-linked immunosorbent assay (ELISA), 109, 125, 127
- Enzymes, 16, 19

- E (cont.)**  
 Eosinophils, 96  
 Epidemics, 119  
 Epidemiological evidence, 108  
 Epithelial, 49  
 Epithelial cell surface receptors, 74  
 Epitopes, 100, 125, 132  
*Escherichia coli*, 8, 30, 36  
*Escherichia coli* DH5 $\alpha$ , 28  
*Escherichia coli* PhoA, 110  
*Escherichia coli* strain 0157:H7, 55  
 Eubacterium saburreum, 66  
 Eukaryotic cells, 6, 11, 57, 91, 92, 148, 149  
 Exopolymerase matrix, 65  
 Exopolysaccharide, 66, 67  
 Exotoxin, 1  
 Exponential growth phase, 37  
 Extracellular DNase, 55  
 Extracellular medium, 11  
 Extracellular milieu, 48  
 Extraintestinal pathogenic *E. coli* (ExPEC), 52
- F**  
 FadL, 29  
 Fetal brain cell adhesion molecules, 120  
 Fibrinolytic factors, 53  
 Fibronectin, 100  
 Filamentous hemagglutinin (FHA), 111  
 Fimbriae, 114  
 Fimbriae/pili (FliC/PilQ), 29  
 Fimbrial proteins, 111  
 Fission of OMVs, 87  
 Fixation, 9  
 Fixative, 9  
 Flagella, 28  
 Flagellin, 96  
 Fluid loss, 109  
 Foreign epitopes, 100  
 Form, 50  
 Formation of biofilms, 65  
 Fosfomycin, 40  
 Functional identity, 6  
 Fusion of OMV, 71, 75  
 Fusogenic capacity, 40
- G**  
*galE* mutant, 67, 114  
*galU*, 67  
 Gastric cells, 38  
 Gastric epithelial cell, 75  
 Gel filtration chromatography, 28  
 Gene disruptions, 82  
 Gene expression, 53, 73  
 Gene transfer, 56  
 Generalized model of biogenesis, 85  
 Genetic engineering, 112  
 Genetic studies, 82  
 Genetic transformation, 55  
 Genetically detoxified endotoxin, 126  
 Genetics of biofilm formation, 66  
 Genomes, 132  
 Genome sequence, 132  
 Gentamicin, 12, 39  
 Gentamicin-induced vesicles, 40  
 Genuine prokaryotic secretion process, 92  
 Gingipains, 66, 114  
 GlcNAc-MurNAc tripeptides, 104  
 Global vaccine strategies, 132  
 Glycoconjugate vaccines, 119  
 Glycopeptides, 29  
 GM1-ganglioside-dependent ELISA, 49  
 GNA1870, 132  
 Gram-negative, 48, 53, 57, 71–74  
 Gram-negative bacteria, 11  
 Gram-positive, 48, 53, 57, 71–74  
 Granules, 5, 6  
 Green fluorescent protein, 55  
 Growth curves, 10
- H**  
 Hapten, 133  
 Heavy chain constant region 1 (CH1), 97  
 Helices, 58  
*Helicobacter pylori*, 36, 50, 74  
 Hemagglutinins, 114  
 Heme, 65  
 Hemolysin, 29  
*Hemophilus*, 55  
*Hemophilus influenzae*, 56, 74, 119  
 Hepatitis B surface antigen, 134  
 Heterologous, 124  
 Heterologous proteins, 57, 58, 110  
 Heterologous vaccine antigens, 134  
 Hexavalent PorA OMV vaccine, 127  
 High-confidence peptide, 28  
 High-throughput expression analysis, 132  
 HlyA, 54  
 HmuY, 65  
*hns*, 36  
 Homologous, 124  
 Host cell receptors, 74  
 Host cells, 74  
 Host complement system, 97  
 Host defense, 95  
 Host immune response, 98

- Host immune system, 53  
 Hostile environmental factors, 48  
 “Housekeeping” proteins, 16  
 Human B-cell receptor, 97  
 Human B cells, 97  
 Human gastric adenocarcinoma epithelial cell line, 103  
 Human gastric epithelium, 50  
 Human gingiva, 38  
 Human glycolipids, 128  
 Human lung epithelial cells, 74  
 Human monocytes, 53  
 Human polymorphonuclear leukocytes, 52  
 Human respiratory pathogen, 96  
 Human skin, 39  
 Human umbilical vein endothelial cells, 74  
 Humoral response, 108  
 Hydrolases, 73  
 Hydrophobic molecules, 93  
 Hydrophobic  $\beta$ -hairpin, 58  
 Hydrophobicity, 28  
 Hyperactivation of the  $\sigma^E$  pathway, 41  
 Hypervesiculation mutants, 84
- I**
- IFN- $\gamma$ , 114  
 IgA protease, 29  
 IgD, 98  
 IgM, 98  
 Ig-superfamily tyrosine-based activation motif or ITAM, 97  
 Ig- $\alpha/\beta$  heterodimer(s), 97  
 IL-8, 102  
 Imbalance, 82  
 Immune complexes, 100  
 Immune factors, 65  
 Immune response, 96  
 Immune-compromised individuals, 110  
 Immunity, 60  
 Immunization with OMVs, 110  
 Immunoblotting of purified OMVs, 49  
 Immunodominant antigens, 132  
 Immunogen, 105  
 Immunogenic, 108  
 Immunogenic OMV proteins, 111  
 Immunogenicity, 113  
 Immunoglobulin A (IgA), 108  
 Immunoglobulin D (IgD)-binding protein MID, 97  
 Immunological memory, 108, 118, 119  
 Immunological responses, 75  
 Immunomodulatory compounds, 20  
 Immunostimulatory activity, 134
- Immunostimulatory complexes, 133  
 Impairment of protein folding, 40  
 In silico analysis, 132  
 Including *Porphyromonas spp.*, 36  
 Infected host, 39  
 Inflammation, 74  
 Inflammatory molecules, 101  
 Inherent property, 9  
 Innate B-cell subsets, 98  
 Innate immune response, 95, 99  
 Innate immune system, 95  
 Inner membrane protein, 16  
 Intact membrane vesicles, 125  
 Integral proteins, 16  
 Interbacterial glue, 65  
 Interleukin, 98  
 Interleukin-12, 102  
 Internalization of vesicles, 97  
 Intestinal epithelial cells, 39  
 Intestinal epithelium, 116  
 Intracellular bacteria, 40  
 Intracellular  $\text{Ca}^{2+}$  influx, 97  
 Intracellular trafficking, 104  
 Intracellular vacuoles, 101  
 Intra-gastric, 110  
 Intramuscular injection, 111  
 Intranasal, 110  
 Intranasal (i.n.) route, 108  
 Intraperitoneal (i.p.) route, 108  
 Invasins, 96  
 Iron-limiting conditions, 39  
 Isoelectric focusing, 28  
 Isoelectric points, 28  
 IV (T4SS), 92
- K**
- Killed whole-cell *V. cholerae* vaccines, 109  
 Killed whole-cell vaccines, 133
- L**
- Lactone ring, 53  
 Lacto-N-neotetraose, 127, 128  
 LamB, 29  
 Leaky membranes, 12  
 Lectin pathway, 99  
*Legionella pneumophila*, 52, 75  
 Lethal aerosol challenge, 113  
 Leukotoxic strains, 36  
 Leukotoxin, 48  
 Lewis antigens, 52, 53  
 Ligands, 93  
 Lighter density fractions, 20

- L** (*cont.*)
- Limulus ameocyte lysate (LAL) assay, 115
  - Lipid A acylation, 126
  - Lipid A modifying enzyme, 112
  - Lipid anchor, 15
  - Lipid raft, 75
  - Lipid, 97
  - Lipid-A, 15
  - Lipids, 8, 15
  - Lipid-tracking dye, 75
  - Lipoglycopeptide, 8
  - Lipo-oligosaccharide (LOS), 98
  - Lipopolysaccharide (LPS), 15, 108, 114
  - Lipoproteins, 15, 16, 18
  - Liposome, 133
  - Liquid chromatography (LC), 28
  - Liquid culture, 37
  - Liquid media, 81
  - Live attenuated vaccines, 133
  - Live-attenuated strains, 113
  - Local disruptions, 86
  - Localized bulging, 86
  - Logarithmic growth, 10
  - Log-phase culture, 115
  - Long-lasting protective immunity, 133
  - Lpp* strains, 83
  - LppA*, 16
  - LppAB*, 83
  - LPS binding protein (LBP), 76
  - LPS core mutants, 38
  - LPS O-antigen, 38
  - LPS phenotype, 67
  - LPS phenotype switching, 38
  - LPS-OMP complex vaccine, 108
  - LpxL1* KO mutant, 127
  - LT, 49
  - Lumens, 19
  - Luminal contents, 47
  - Luminal vesicle marker, 57
  - Lymphocytes, 96
  - Lysine, 8
  - Lysine-limiting conditions, 8
  - Lysine-requiring mutant, 8
  - Lysozyme-treated, 10
- M**
- Macrophage infectivity potentiator (Mip), 29, 52
  - Macrophages, 96
  - Major histocompatibility complex class II (MHC-II), 102
  - MALDI-TOF mass spectrometric techniques, 19
  - MALDI-TOF/TOF-MS, 111
  - Mammalian cell, 58
  - Mannose-binding lectin, 100
  - Mass spectrometry, 28
  - Mast cells, 96
  - Mechanism of energy transfer, 88
  - Medical applications, 95
  - Melioidosis, 112
  - Membrane attack complex, 100
  - Membrane filter, 20, 28
  - Membrane instability, 12, 36
  - Membrane integrity, 86
  - Membrane sac, 3
  - Membrane-bound antisigma factor, 40
  - Membrane-bound vesicles, 92
  - Membrane-involving secretion processes, 92
  - Meningitis, 39
  - Meningococcal capsular PS, 123
  - Meningococcal vaccine, 122
  - Meso-diaminopimelic acid, 73
  - Met, 29
  - Metal shadowing, 3
  - Mex, 29
  - Mg<sup>2+</sup> starvation, 83
  - Mice, 108
  - Microanatomical studies, 91
  - Microbial pathogenesis, 65
  - Microflora, 65
  - Microvesicles, 130
  - MID-BCR, 98
  - Misfolded proteins, 84
  - Mitogen-activated protein (MAP)-kinase, 97
  - Mitogenic B-cell response, 98
  - Mitomycin C, 40
  - MltA, MipA, MltE, 84
  - Model of OMV biogenesis, 85
  - Molecular weights, 28
  - Molecules, 53
  - Monoclonal antibody, 118
  - Monocytes, 52
  - Monomeric form, 58
  - Moraxella catarrhalis*, 53, 74, 96
  - mORCVAX, 109
  - Morexella OMVs, 100
  - Motility proteins, 29
  - Mouse fibroblast cells, 39
  - Mouse lethality test, 115
  - Mouse model of meningococcal, 108
  - msbB* mutant, 115
  - MSHA, 67
  - Mtr, 29
  - Mucosal adjuvant, 114
  - Mucosal epithelial cells, 96
  - Mucosal routes, 116

Multidrug efflux pumps, 29  
 Multidrug-resistant strains, 110  
 Multi-immunogenic OMVs, 115  
 Multilayered structure, 10  
 Multiple antigens, 60  
 Multiple bacterial antigens, 111  
 Multiple signaling pathways, 97  
 Multisubunit toxins, 92  
 Murein hydrolases, 29, 48, 84  
 Myeloid differentiation 88 (MyD88), 98

**N**

NAD-glycohydrolase, 52  
 Nanoparticle- conjugated OMV, 117  
 NarE, 52  
 Native OMV, 82, 108, 120  
 Native OMV vaccines, 126  
 Natural blebs, 12  
 Natural killer cells, 96  
 Negatively stained, 9  
*Neisseria gonorrhoeae*, 55  
*Neisseria lactamica*, 98  
*Neisseria meningitidis*, 28, 95, 100, 105, 125, 127  
*Neisseria spp.*, 36  
 Neisserial LPS, 128  
 Neonatal meningitis, 76  
 Neutrophil, 96, 102  
 Neutrophil recruitment, 96  
 Nitric oxide (NO), 102  
*nlpA*, 84  
 NmpC, 16, 83  
 NOD1-dependent signaling, 104  
 NOD1 signaling, 103  
 Non diffusible enzymes, 92  
 Nonavalent OMV vaccine, 128  
 Noncapsular antigens, 108  
 Noncapsular vaccines, 120  
 Nonpathogenic, 36  
 Nonphagocytic epithelial cells, 103  
 Nonreplicating vaccines, 95  
 Nonvesicular component, 20  
 Nonviable vesicles, 118  
 Norfloxacin, 40  
 N-terminal signal peptide, 92  
 N-terminus of ClyA, 60  
 Nuclear area, 9  
 Nuclear factor (NF)κB, 97  
 Nucleotide binding oligomerization domain 1 (NOD1), 103  
 Nutrient acquisition, 73  
 Nutrient starvation, 67

**O**

O-antigen, 67  
 Ocular route, 117  
 Oligomeric pore assemblies, 58  
 Oligomeric pore complex, 58  
 OM integrity, 83  
 OM-peptidoglycan links, 84, 86  
 OMP biogenesis, 40  
 Omp, 16, 29, 76  
 OmpA, 16, 83  
 OmpC, 16, 83  
 OM-peptidoglycan links, 84  
 OM-peptidoglycan-linking proteins, 84  
 OmpF, 16, 83  
 OM-PG, 83  
 OM-PG-IM associations, 83  
 OmpX, 16, 83  
 OMV.LT complex, 75  
 OMV-associated PGs, 104  
 OMV-associated toxins, 48  
 OMV-based vaccine, 124  
 OMV-CT complex, 49  
 OMV-derived vaccines, 133  
 OMV-mediated plasmid transfer, 55  
 One dimensional (1-D) SDS-PAGE, 28  
 OprF, 16, 18, 29  
 OprI, 16  
 OprL, 16  
 Opsonic activity, 126  
 Opsonins, 100  
 Opsonization, 99  
 Optical density, 10  
 Oral bacteria, 66  
 Oral immunization, 110  
 Organophosphorus hydrolase (OPH), 58, 60  
 Outer membrane, 15  
 Outer membrane protein, 16, 108  
 Outer membrane vesicles, 3, 114  
 Overabundance, 84  
 Oxygen stress, 38

**P**

Packaging, 47  
*pagL* gene, 112  
 Pal, 83  
 Paraoxon, 58  
 Paratyphi A, 58  
 Passive immunization, 118  
 Pathogen-associated molecular patterns (PAMPs), 96  
 Pathogenic, 36  
 Pathogenic bacteria, 20

- P** (*cont.*)
- Pathogen-specific immunity, 115
  - Pattern recognition receptors (PRR), 96
  - Penicillin-resistance gene, 55
  - Penicillin-sensitive gonococci, 55
  - Penta-acylated LOS, 112
  - Penta-acylated LPS, 115
  - Peptic ulcer, 38
  - Peptide, 28
  - Peptidoglycan- associated lipoprotein Pal, 16
  - Peptidoglycan hydrolase, 66
  - Peptidoglycan, 16, 29, 73
  - Periodontal disease, 66
  - Periodontal disease vaccine, 114
  - Periodontal epithelial cells, 53
  - Periodontitis, 113
  - Periplasm, 8, 16
  - Periplasmic cargo, 54
  - Periplasmic constituents, 19
  - Periplasmic protein, 54
  - Pertactin (PRN), 111
  - Pertussis toxin (PT), 92, 111
  - PG layer, 16
  - Phage DNA, 55
  - Phage infections, 81
  - Phage K139.cm9, 67
  - Phagocytes, 100, 101
  - Phagocytic cells, 96
  - Phagocytosis, 100
  - Pharyngeal lymphoid tissue, 96
  - Phenol-water extracted, 10
  - PhoP/PhoQ, 101
  - Phosphoinositide 3-kinase (PI3-K), 97
  - Phospholipase C (PLC) c2, 97
  - Phospholipids, 15
  - Phosphorylation of kds, 49
  - Physiological roles, 95
  - Pili, 28
  - Pilus biosynthesis genes, 56
  - Pinocytosis, 91
  - Placebo-controlled, 122
  - Plasma, 100
  - Plasma membrane, 5
  - Plasmid conjugal transfer, 56
  - Plasmid pAK 1900, 55
  - Plasmid replication, 56
  - Plasmid-containing OMVs, 55
  - Plasmids, 55
  - Plasmolysis, 5
  - Poly (I: C), 114
  - Poly methylvinylether-co-maleic anhydride (PVM/MA) nanoparticles, 117
  - Polyclonal anti-CT antibody, 49
  - Polysaccharides, 8
  - Polysaccharide-based vaccines, 105
  - Polyvinylidene fluoride (PVDF) filter, 117
  - PorA, 29
  - PorA immunodominance, 127
  - PorA protein, 124
  - PorA serosubtypes, 128
  - PorA variable region, 126
  - PorA variants, 124
  - PorB, 29
  - PorB proteosome, 98
  - Pore-forming cytotoxin, 58
  - Porins, 15, 16
  - Porphyromonas gingivalis*, 53, 66, 82, 113
  - Postvaccination, 124
  - PQS incorporation, 87
  - “Predatory”, 48
  - Predatory activities, 47
  - Prevotella intermedia*, 66
  - Procoagulant, 53
  - Proinflammatory chemical mediators, 96
  - Proinflammatory cytokine, 98
  - Protease, 39, 40, 52
  - Protease/chaperone proteins (DegQ/SurA), 29
  - Protective Ags, 115
  - Protective efficacy, 113
  - Protective immune response, 133
  - Protective immunity, 117
  - Protective induced immunity, 110
  - Protein accumulation, 41
  - Protein families, 29
  - Protein hit score (PHS), 28
  - Protein profile, 28
  - Protein transport, 92
  - Protein tyrosine kinases (PTKs), 97
  - Protein–protein interactions, 16, 83
  - Proteins, 8
  - Proteoliposomes, 133
  - Proteome, 28
  - Proteomic analysis, 29, 132
  - Proteomic profile, 20
  - Proteosomes, 133
  - Protoplasm, 5
  - Pseudomonas aeruginosa*, 16, 18, 82
  - Pseudomonas* quinolone signal (PQS), 53, 74
  - Purification of OMVs, 30
  - Purified B polysaccharide, 108
  - Putative cellular localization, 130
- Q**
- Quorum sensing (QS), 53, 72, 73
  - Quorum sensing molecule, 52, 87



**R**

Rabbit apocrine sweat glands, 91  
 Rabbit ileal loop model, 109  
 Receptor-associated factor 6 (TRAF 6), 98  
 Receptor-mediated endocytic pathway, 75  
 Receptor-mediated endocytosis, 71  
 Receptors, 15  
 Recognition signal, 96  
 Recombinant expression vector, 115  
 Recombinant OMVs, 120  
 Recombinant protein expression, 132  
 Redox status, 58  
 Regulation of protein synthesis, 30  
 Regulator of OMV formation, 83  
 Rehydration therapy, 109  
 Release of blebs, 8  
 Reverse pinocytosis, 11  
 Reverse vaccinology, 132  
 Reversed pinocytosis, 91  
 Ribosomal content, 10  
 Ribosomal proteins, 29  
 Ribosome, 9  
 RmpM, 134  
 RseA, 40  
 RTX, 48  
 Rugose colony morphology, 67

**S**

Safety and efficacy trials, 132  
 Safety and immunogenicity, 108  
 Safety profiles, 122  
 Safety/efficacy of OMV vaccines, 112  
*Salmonella enterica*, 58  
*Salmonella spp.*, 16  
*Salmonella typhimurium*, 39, 101  
 Salts-glycerol medium, 8  
 SBA assay, 119  
 Scavenging proteases, 73  
 SDS-polyacrylamide gel electrophoresis (SDS-PAGE), 19, 73, 111  
 Sec or Tat signal sequence, 92  
 Secretion mechanism, 91  
 Self-adjutant properties, 118  
 Self-encoded  $\beta$ -barrel structure, 92  
 Sephacryl S500 column, 28  
 Septic infection, 39  
 Sequence homology, 29  
 Serum bactericidal activity, 118  
 Serum IgG and IgA, 113  
 Serum resistance, 100  
 Set of genes, 40  
 Seventh secretion mechanism, 91  
 Shancol, 109

Shiga toxin, 2, 40, 48, 49  
*Shigella dysenteriae*, 40  
*Shigella dysenteriae* serotype 1, 48  
*Shigella flexneri*, 116  
*Shigella spp.*, 36  
 Shigellosis, 116  
 Signaling cascade, 96  
 Signaling molecules, 53  
 Single-chain antibody fragment (ScFv.Dig), 60  
 Site of division, 37  
 Six major secretory pathways, 92  
 SLP, 84  
 SLT, 29  
 Small intestine mucosa, 38  
 Small noncoding s-RNA gene, 41  
 Smooth colony morphology, 67  
 Sodium dodecyl sulphate, 52  
 Solid agar, 81  
 Solid growth media, 37  
 Soluble cargo, 49  
 Soluble periplasmic fraction, 54  
 Soluble proteins/serum proteins, 96  
 Sorting mechanism, 18, 85  
 Sorting processes, 81  
 Spheroplasts, 9, 10  
 s-RNA gene, 83  
 Stacked leaflets, 8  
*Staphylococcus aureus*, 66  
 Stationary phase of growth, 9  
 Streptococcus species, 66  
 Stress response, 40  
 Stress response pathways, 40  
 Stress signal transmitters, 40  
 Stressors, 40  
 Suboptimal fixation, 9  
 Subunit vaccination, 132  
 Subunit vaccines, 133  
 Sucrose gradient, 112  
 Surface blebs, 8  
 Surface immunoglobulin (Ig) molecule, 97  
 Surrogate marker of protection, 119  
 Syphilis, 117  
 Systemic antibody, 108  
 Systemic response, 127

**T**

T2SS pathway, 92  
 T4SS mechanism, 92  
 "Tailor-made" OMV vaccine, 124  
*Tannerella forsythia*, 53, 66  
 Target cell, 73, 75, 93  
 T-cell immunity, 133  
 T-cell memory responses, 113

- T** (*cont.*)  
 TcpP/H, 109  
 Tetanus toxoid, 120  
 Tetra-acylated LOS, 112  
 Thyroid cell, 91  
 Tissue fluids, 100  
 TLR2, 97  
 TLR9, 97  
 TLR pathways, 104  
 Tohama vaccine strain, 111  
*tol/pal* system, 83  
*tolA* deletion, 83  
*tolB*, 83  
*tolC*, 29  
 Toll-like receptor 3 (TLR3), 114  
 Toll-like receptor (TLR)-dependent manner, 97  
*tol-pal* genes, 83  
 Tonsillar B cells, 97  
 Tonsillar mucosal mononuclear cells (TNMCs), 98  
 Toxin, 19, 49  
 Toxic misfolded proteins, 41  
 ToxR/S, 109  
 Transcription factors, 98  
 Transcriptional activation, 40  
 Transcriptional regulator, 53  
 Transduction of energy, 92  
 Transformation, 56  
 Transformation of genes, 55  
 Transforming growth factor b-activated kinase 1 (TAK-1), 98  
 Transglycosylases, 83  
 Translocation of heterologous proteins, 60  
 Transposon insertion mutants, 36  
 Transposon mutagenesis, 67  
 Transposon mutagenesis screen, 41  
*Treponema denticola*, 53  
*Treponema pallidum*, 117  
*Treponema pallidum* rare outer membrane proteins (TROMPs), 117  
 Triggering of cell-mediated immunity, 95  
 Trilamellar structure, 4, 15  
 Trimeric, 16  
 Truncated form of VacA, 50  
 Truncation mutants, 84  
 Trypsin digestion, 28  
 Tumor necrosis factor (TNF), 98  
 Turgor pressure, 82  
 Turnover of PG, 82  
 Two-dimensional gel electrophoresis, 28  
 Type I secretion process, 50  
 Type II (T2SS), 92  
 Type II general secretory pathway, 49  
 Type IV (T4SS), 92  
 Type IV pilus (mannose-sensitive hemagglutinin pilus MSHA), 67  
 Type V (T5SS), 92  
 Type VII (T7SS) secretion pathway, 93  
 Typhi, 58  
 Tyrosine kinase (TKs), 97
- U**  
 Ubiquitous surface protein (Usp), 100  
 UDP-galactose, 67  
 UDP-glucose, 67  
 Ultracentrifugation, 20, 115  
 Ultrastructure of plaque, 38  
 Ultrastructure of *Vibrio cholerae*, 1  
 Ultrathin sectioning, 3  
 Unbalanced growth, 8  
 Unfixed cells, 9  
 Unfolded proteins, 81  
 Unnatural bleb formation, 12  
 Unnatural OMVs, 36, 82  
 Unnatural vesicle production, 39  
 UspA1, 100  
 UspA2, 100  
 UspA2H, 100
- V**  
 V (T5SS), 92  
 VacA, 39, 48  
 VacA-containing OMVs, 54  
 Vaccine candidate, 108, 113  
 Vaccine formulation, 113  
 Vaccines, 60  
 Vacuolating cytotoxin, 39  
 Vacuolating cytotoxin, VacA, 50  
 Vacuoles, 75  
 Vacuolization in HEp-2 cells, 50  
 Vehicle for translocation, 60  
 Veillonella cells, 10  
 Vesicle formation, 2  
 Vesicle-associated toxins, 49  
 Vesicular proteins, 29  
 Vesiculation, 12, 36  
 Vesiculation or OMV, 36  
 Vesiculation phenotypes, 38  
*Vibrio cholerae*, 1, 109  
*Vibrio cholerae* biotype ElTor, 67  
*Vibrio cholerae* El Tor N16961, 110  
*Vibrio cholerae* O1 strain A1552, 41, 83  
*Vibrio cholerae* O139 strain MO10, 67  
*Vibrio cholerae* O395, 49  
*Vibrio spp.*, 36

Virulence, [19](#)  
Virulence factor, [19](#), [54](#)  
Virulence regulatory factor, [36](#)  
Viruses, [6](#), [91](#)  
Vitronectin, [100](#)  
VPS exopolysaccharide, [67](#)  
*vps genes*, [67](#)  
*vps*-independent biofilm, [67](#)  
*vrrA*, [41](#), [83](#)  
VrrA RNA, [41](#)

**W**

Western blotting, [83](#)  
Whole-cell enzyme-linked, [108](#)  
World Health Organization, [116](#)

**X**

*Xanthomonas campestris*, [54](#)  
*Xenorhabdus nematophilus*, [52](#)

**Y**

Y1 adrenal cells, [49](#)  
*Yersinia enterocolitica*, [57](#)  
*yfgL*, [83](#)  
*ypjA*, [84](#)

**Z**

Zwitterionic detergent, [122](#)